Eisai Co., Ltd. and Biogen Inc. announced on January 6th that under the Accelerated Approval Pathway the U.S. Food and Drug Administration (FDA) has approved lecanemab-irmb, which has the brand name in the United States of LEQEMBITM, for the treatment of Alzheimer’s disease. The approval is based on Phase 2 data that demonstrated that LEQEMBI reduced the accumulation of Aβ plaque in the brain, a defining feature of Alzheimer’s disease. Newt’s guest is Dr. Marwan Sabbagh, MD. He is a behavioral neurologist in the Alzheimer’s and Memory Disorders Program and a professor in the Department of Neurology at Barrow Neurological Institute and was one of the leading doctors of the study.

Episode 1051: The End of a Fair Price — Lindsay Owens on How Companies Use Your Data to Charge You More
40:28

Episode 1050: The Midterms, 27 Days Out — McLaughlin and Sosnik on Who Will Control Congress
41:35

Episode 1049: The Exhausted Majority — Who Independents Really Are and Why They'll Decide 2026
35:24